Last reviewed · How we verify

Hyuk moon Kim — Portfolio Competitive Intelligence Brief

Hyuk moon Kim pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
early leukostim early leukostim marketed Growth factor G-CSF receptor Oncology
late leukostim late leukostim marketed Growth factor G-CSF receptor Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Adocia · 1 shared drug class
  2. Australasian Gastro-Intestinal Trials Group · 1 shared drug class
  3. Centre Oscar Lambret · 1 shared drug class
  4. Chinese PLA General Hospital · 1 shared drug class
  5. Genzyme, a Sanofi Company · 1 shared drug class
  6. SVS Institute of Dental Sciences · 1 shared drug class
  7. Soligenix · 1 shared drug class
  8. Xiamen Amoytop Biotech Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hyuk moon Kim:

Cite this brief

Drug Landscape (2026). Hyuk moon Kim — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hyuk-moon-kim. Accessed 2026-05-16.

Related